Shattuck Labs, Inc. Banner Image

Shattuck Labs, Inc.

  • Ticker STTK
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Shattuck Labs, Inc. Logo Image
  • 51-200 Employees
  • Based in Austin, Texas
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatoryMore molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to cell-based antigens for the treatment of patients with cancer and autoimmune disease. Shattuck has offices in both Austin, Texas and Durham, North Carolina.
Shattuck Labs, Inc.

Most Recent Annual Report

Shattuck Labs, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Shattuck Labs, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!